TACTI-003 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Randomized, Phase IIb Trial to Investigate a Soluble LAG-3 Fusion Protein, Eftilagimod Alpha (Efti; IMP321) in Combination With Pembrolizumab (PD-1 Antagonist) for First Line Treatment of Subjects With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Latest Information Update: 21 Dec 2024
Price :
$35 *
At a glance
- Drugs Eftilagimod alpha (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms TACTI-003
- Sponsors Immutep Limited
- 12 Dec 2024 According to a an Immutep Limited media release, data form this trial were presented at the ESMO Immuno-Oncology (IO) Annual Congress 2024.
- 12 Dec 2024 Results presented in an Immutep Limited media release.
- 28 Oct 2024 According to a an Immutep Limited media release, new data of cohort B from this study will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2024 taking place 11-13 December in Geneva, Switzerland.